https://thomson-walsh.com/2026-09-07T08:28:01.615Z https://thomson-walsh.com/about/ https://thomson-walsh.com/contacts/ https://thomson-walsh.com/authors/ https://thomson-walsh.com/categories/pharmacovigilance/2026-09-07T07:31:03.716Z https://thomson-walsh.com/categories/medical-affairs/2026-09-07T08:28:01.615Z https://thomson-walsh.com/categories/regulatory-compliance/2026-09-07T05:12:01.900Z https://thomson-walsh.com/categories/clinical-development/2026-09-07T05:57:02.112Z https://thomson-walsh.com/categories/medical-consulting/2026-09-07T06:32:21.174Z https://thomson-walsh.com/articles/medical-information-inquiries-inside/2026-09-07T08:28:01.615Zhttps://thomson-walsh.com/assets/medical-information-inquiries-inside.webp https://thomson-walsh.com/articles/risk-minimisation-measures-what/2026-09-07T07:31:03.716Zhttps://thomson-walsh.com/assets/risk-minimisation-measures-what.webp https://thomson-walsh.com/articles/fpm-certification-is-it-necessary/2026-09-07T06:32:21.174Zhttps://thomson-walsh.com/assets/fpm-certification-is-it-necessary.webp https://thomson-walsh.com/articles/ind-safety-reporting-essential-actions/2026-09-07T05:57:02.112Zhttps://thomson-walsh.com/assets/ind-safety-reporting-essential-actions.webp https://thomson-walsh.com/articles/disease-awareness-vs-promotion-two/2026-09-07T05:12:01.900Zhttps://thomson-walsh.com/assets/disease-awareness-vs-promotion-two.webp https://thomson-walsh.com/articles/medical-education-grant-breaches-a/2026-09-07T04:38:27.222Zhttps://thomson-walsh.com/assets/medical-education-grant-breaches-a.webp https://thomson-walsh.com/articles/medical-advisory-vetting-evaluating/2026-09-07T03:48:59.598Zhttps://thomson-walsh.com/assets/medical-advisory-vetting-evaluating.webp https://thomson-walsh.com/articles/fda-mandates-boxed-warning-for/2026-09-07T03:12:04.393Zhttps://thomson-walsh.com/assets/fda-mandates-boxed-warning-for.webp https://thomson-walsh.com/articles/project-optimus-dosing-what-regulators/2026-09-07T02:06:59.197Zhttps://thomson-walsh.com/assets/project-optimus-dosing-what-regulators.webp https://thomson-walsh.com/articles/scientific-communication-platforms/2026-09-07T01:03:07.600Zhttps://thomson-walsh.com/assets/scientific-communication-platforms.webp https://thomson-walsh.com/articles/in-house-vs-outsourced-pv/2026-09-06T23:53:02.099Zhttps://thomson-walsh.com/assets/in-house-vs-outsourced-pv.webp https://thomson-walsh.com/articles/clinical-asset-diligence-a-biopharma/2026-09-06T22:56:47.273Zhttps://thomson-walsh.com/assets/clinical-asset-diligence-a-biopharma.webp https://thomson-walsh.com/articles/ema-releases-sponsor-guidance-for/2026-09-06T15:47:04.363Zhttps://thomson-walsh.com/assets/ema-releases-sponsor-guidance-for.webp https://thomson-walsh.com/articles/dsmb-stopping-boundaries-what-trial/2026-09-06T10:41:01.289Zhttps://thomson-walsh.com/assets/dsmb-stopping-boundaries-what-trial.webp https://thomson-walsh.com/articles/pharma-employee-social-media-where/2026-09-06T10:22:32.170Zhttps://thomson-walsh.com/assets/pharma-employee-social-media-where.webp https://thomson-walsh.com/articles/msl-kpi-frameworks-for-measuring/2026-09-06T09:57:00.924Zhttps://thomson-walsh.com/assets/msl-kpi-frameworks-for-measuring.webp https://thomson-walsh.com/articles/locum-medical-advisory-vs-retained/2026-09-06T09:30:57.265Zhttps://thomson-walsh.com/assets/locum-medical-advisory-vs-retained.webp https://thomson-walsh.com/articles/protocol-design-mistakes-that-stall/2026-09-06T08:49:54.918Zhttps://thomson-walsh.com/assets/protocol-design-mistakes-that-stall.webp https://thomson-walsh.com/articles/medical-signatory-review-inside-the/2026-09-06T08:27:19.251Zhttps://thomson-walsh.com/assets/medical-signatory-review-inside-the.webp https://thomson-walsh.com/articles/field-medical-insights-why-qualitative/2026-09-06T07:15:29.344Zhttps://thomson-walsh.com/assets/field-medical-insights-why-qualitative.webp https://thomson-walsh.com/articles/bridging-the-gap-between-ai/2026-09-06T07:13:01.275Zhttps://thomson-walsh.com/assets/bridging-the-gap-between-ai.webp https://thomson-walsh.com/articles/psur-eurd-alignment-practical-steps/2026-09-06T06:33:20.936Zhttps://thomson-walsh.com/assets/psur-eurd-alignment-practical-steps.webp https://thomson-walsh.com/articles/adaptive-vs-fixed-trial-design/2026-09-06T05:54:03.328Zhttps://thomson-walsh.com/assets/adaptive-vs-fixed-trial-design.webp https://thomson-walsh.com/articles/advisory-board-failures-a-medical/2026-09-06T05:09:08.605Zhttps://thomson-walsh.com/assets/advisory-board-failures-a-medical.webp https://thomson-walsh.com/articles/pharmacovigilance-system-master-file/2026-09-06T04:45:59.702Zhttps://thomson-walsh.com/assets/pharmacovigilance-system-master-file.webp https://thomson-walsh.com/articles/eu-regulatory-shift-aims-to/2026-09-05T23:24:16.031Zhttps://thomson-walsh.com/assets/eu-regulatory-shift-aims-to.webp https://thomson-walsh.com/articles/key-regulatory-updates-from-the/2026-09-05T23:22:16.552Zhttps://thomson-walsh.com/assets/key-regulatory-updates-from-the.webp https://thomson-walsh.com/articles/eudravigilance-signal-detection-what/2026-09-04T14:02:00.000Zhttps://thomson-walsh.com/assets/eudravigilance-signal-detection-what.webp https://thomson-walsh.com/articles/fractional-cmo-strategy-actionable-steps/2026-09-03T09:37:00.000Zhttps://thomson-walsh.com/assets/fractional-cmo-strategy-actionable-steps.webp https://thomson-walsh.com/articles/investigator-initiated-studies-internal/2026-09-03T07:42:00.000Zhttps://thomson-walsh.com/assets/investigator-initiated-studies-internal.webp https://thomson-walsh.com/articles/promotional-review-pitfalls-a-pmcpa/2026-08-30T08:26:00.000Zhttps://thomson-walsh.com/assets/promotional-review-pitfalls-a-pmcpa.webp https://thomson-walsh.com/articles/surrogate-endpoints-vs-overall-survival/2026-08-27T07:07:00.000Zhttps://thomson-walsh.com/assets/surrogate-endpoints-vs-overall-survival.webp